Semorinemab (RG6100)

Migration, Crosslink

📖

Semorinemab (RG6100)

active

wiki page Created: 2026-04-02T07:19:00 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-semorinemab

📖 Wiki Page

therapeutic2319 wordssynced 2026-04-02

Semorinemab (RG6100)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Semorinemab (RG6100)</th>
</tr>
<tr>
<td class="label">Group</td>
<td>CDR-SB Change (95% CI)</td>
</tr>
<tr>
<td class="label">Placebo</td>
<td>2.19 (1.74-2.63)</td>
</tr>
<tr>
<td class="label">1500 mg</td>
<td>2.36 (1.83-2.89)</td>
</tr>
<tr>
<td class="label">4500 mg</td>
<td>2.36 (1.92-2.79)</td>
</tr>
<tr>
<td class="label">8100 mg</td>
<td>2.41 (1.88-2.94)</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab (RG6100)</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB092)</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Lomecelb</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">FcR binding</td>
<td>High</td>
</tr>
<tr>
<td class="label">Complement activation</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">ADCC activity</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~21 days</td>
</tr>
<tr>
<td class="label">Brain delivery</td>
<td>Limited</td>
</tr>
</table>

...

Semorinemab (RG6100)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Semorinemab (RG6100)</th>
</tr>
<tr>
<td class="label">Group</td>
<td>CDR-SB Change (95% CI)</td>
</tr>
<tr>
<td class="label">Placebo</td>
<td>2.19 (1.74-2.63)</td>
</tr>
<tr>
<td class="label">1500 mg</td>
<td>2.36 (1.83-2.89)</td>
</tr>
<tr>
<td class="label">4500 mg</td>
<td>2.36 (1.92-2.79)</td>
</tr>
<tr>
<td class="label">8100 mg</td>
<td>2.41 (1.88-2.94)</td>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Semorinemab (RG6100)</td>
<td>Roche/Genentech</td>
</tr>
<tr>
<td class="label">Gosuranemab (BIIB092)</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Lomecelb</td>
<td>Lilly</td>
</tr>
<tr>
<td class="label">Tilavonemab (ABBV-8E12)</td>
<td>AbbVie</td>
</tr>
<tr>
<td class="label">FcR binding</td>
<td>High</td>
</tr>
<tr>
<td class="label">Complement activation</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">ADCC activity</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~21 days</td>
</tr>
<tr>
<td class="label">Brain delivery</td>
<td>Limited</td>
</tr>
</table>

Semorinemab (development code RG6100) is a humanized anti-tau monoclonal antibody developed by [Roche](/companies/roche) and Genentech for the treatment of Alzheimer's disease and other tauopathies[@semorinemab2021][@semorinemab2022]. It represents one of the most advanced anti-tau immunotherapy programs to have completed Phase II clinical trials, providing critical learnings about tau-targeting strategies in neurodegenerative disease.

Tau protein pathology is a hallmark of Alzheimer's disease and correlates strongly with cognitive decline[@tauPropagation2019]. The prion-like propagation of pathological tau between connected brain regions provides a rationale for antibody-based therapies that target extracellular tau species[@prionLikeTau2021]. Semorinemab was designed to intercept these propagating tau species, potentially slowing or halting the spread of tau pathology throughout the brain.

Mechanism of Action

Tau Biology and Pathogenesis

The tau protein is a microtubule-associated protein expressed predominantly in [neurons](/entities/neurons) where it stabilizes microtubules in the axonal compartment[@tauIsoforms2020]. In Alzheimer's disease and related tauopathies, tau undergoes pathological transformations including hyperphosphorylation, aggregation into neurofibrillary tangles, and self-propagation in a prion-like manner[@tauPropagation2019].

Key aspects of tau pathology relevant to antibody-based therapy include:

Tau isoforms: Six isoforms of tau exist in the human brain, generated by alternative splicing of the [MAPT](/genes/mapt) gene. These range from 352 to 441 amino acids[@tauIsoforms2020].
Pathological species: Soluble tau oligomers are considered highly toxic and may represent the most pathogenic species that spread between neurons[@tauOligomers2022].
Prion-like propagation: Pathological tau can template the conversion of normal tau to abnormal forms, allowing spread between connected brain regions[@prionLikeTau2021].
Temporal progression: Tau pathology spreads in a characteristic pattern from the entorhinal cortex to the hippocampus and neocortex, correlating with clinical progression[@tauBiomarkers2023].

Antibody Design and Target Engagement

Semorinemab was engineered with specific properties to maximize therapeutic potential[@semorinemab2021]:

Target epitope: The antibody binds to the N-terminal domain of tau, a region exposed in extracellular tau species released during synaptic activity
Isoform coverage: Binds all six human tau isoforms, ensuring broad coverage of pathological species
Isotype: Immunoglobulin G4 (IgG4) backbone - chosen to minimize Fc-mediated effector functions, potentially reducing inflammatory side effects[@igg4Therapeutics2021]
Mechanism: Aims to neutralize extracellular tau species that propagate between neurons, preventing the spread of tau pathology throughout connected brain networks

The choice of IgG4 isotype was strategic - IgG4 antibodies have reduced ability to engage complement and Fc gamma receptors, potentially leading to a cleaner safety profile compared to IgG1-based antibodies[@igg4Therapeutics2021]. This is particularly important for CNS-targeted antibodies that may cause infusion-related reactions or cytokine release.

Preclinical Characterization

Preclinical studies demonstrated that murine versions of semorinemab could reduce tau pathology in transgenic mouse models after repeated dosing[@semorinemab2021]. Target engagement was confirmed in:

Transgenic mouse models with tau pathology
Nonhuman primates (pharmacokinetics and target engagement)
Human tissue studies

The antibody demonstrated ability to protect neurons against tau oligomer-induced neurotoxicity in neuron-microglia coculture systems, suggesting potential for disease modification beyond simply clearing existing pathology[@semorinemab2021].

Clinical Development

Phase I Trial

A first-in-human Phase I study characterized the safety, tolerability, pharmacokinetics, and pharmacodynamics of semorinemab in healthy volunteers and patients with Alzheimer's disease[@semorinemab2021].

Study Design:

Single and multiple ascending dose cohorts
Tested single doses up to 16,800 mg
Tested multiple doses totaling 33,600 mg over one month
Both healthy volunteers and AD patients enrolled

Key Findings:

No concerning safety signals were observed at any dose level
Target engagement confirmed via dose-dependent increases in systemic tau (indicating antibody binding and clearance of tau)
Higher tau concentrations seen in AD patients versus healthy controls, confirming the presence of excess extracellular tau in AD
Dose-proportional pharmacokinetics observed
Evidence of target engagement in both plasma and CSF

Publication: The Phase I results were published in Science Translational Medicine in May 2021[@semorinemab2021].

Phase II LAURIET Trial

The Phase II LAURIET trial (TAU-ROCHE-001) was a randomized, double-blind, placebo-controlled study evaluating semorinemab in individuals with prodromal to mild Alzheimer's disease[@semorinemab2022].

Trial Design:

97 sites across North America, Europe, and Australia
Enrollment period: 2017-2020
Participants: n=422 (mean age 69.6 years, 55.7% female)
Entry criteria: prodromal to mild AD, MMSE 20-30, confirmed β-amyloid positivity
Tau PET burden assessed at baseline using [^18F]flortaucipir

Dosing Regimen:

Four dose arms: placebo, 1500 mg, 4500 mg, 8100 mg
Every 2 weeks for 3 infusions, then every 4 weeks through week 73
Total treatment duration: 73 weeks

Primary Outcome Results (Clinical Dementia Rating - Sum of Boxes, CDR-SB): Conclusion: Semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period[@semorinemab2022].

Secondary and Exploratory Analyses:

Antibody demonstrated clear engagement with tau target
Effects observed on plasma and CSF biomarkers, indicating target engagement despite lack of clinical efficacy
Reduced CSF soluble tau species in treatment groups
Plasma tau increased in dose-dependent manner (consistent with antibody-tau complex formation and reduced clearance)

Safety Profile:

Adverse event rates similar across groups (placebo: 93.1%; semorinemab: 88.8-94.7%)
Generally well-tolerated across all dose levels
No dose-limiting toxicities identified

Publication: Results published in JAMA Neurology in 2022[@semorinemab2022].

Biomarker Studies

Subsequent analyses have examined the pharmacodynamic effects of semorinemab on various biomarkers[@semorinemab2024a][@semorinemab2024b]:

CSF Complement Study:

Investigated complement pathway activity in AD patient CSF
All measured CSF complement proteins (C4, C3, Factor B, and cleavage fragments) were elevated in AD versus cognitively unimpaired subjects
C4a showed the most robust increase
Baseline complement levels correlated with neuro-axonal degeneration and glial activation biomarkers
Semorinemab did not have significant pharmacodynamic effect on CSF complement proteins

Biomarker Implications:
The disconnect between biomarker changes (target engagement) and clinical outcomes highlights a fundamental challenge in AD drug development - demonstrating that target modulation translates to clinical benefit remains difficult[@failAD2023].

Tau PET Biomarkers in Clinical Trials

Clinical trials utilized tau PET imaging to assess disease status and treatment effects:

Baseline Assessment:

[^18F]flortaucipir (also known as AV-1451 or flortaucipir F-18) used to quantify tau burden at baseline
Tau PET signal correlates with neurofibrillary tangle density
Used for patient enrichment and stratification

Longitudinal Changes:

Tau PET used to track changes in tau accumulation over time
Relationship between tau PET signals and clinical outcomes examined
Provides in vivo measure of tau pathology spread

Clinical Utility:
Tau PET imaging has become essential for AD clinical trials, enabling:

Patient selection for tau-positive individuals
Disease staging based on tau burden
Monitoring of potential treatment effects on tau pathology[@tauBiomarkers2023]

Comparison with Other Anti-Tau Approaches

Semorinemab represents one of several anti-tau antibody strategies that have been tested in clinical trials. Understanding how different approaches differ provides context for interpreting results:

The consistent failure of N-terminal targeting antibodies suggests that either:

The extracellular tau species being targeted are not the primary drivers of clinical decline

Timing of intervention may be critical - patients may have progressed beyond the point of benefit

Better patient selection based on tau burden and disease stage may be needed

Current Status and Future Directions

Semorinemab completed Phase II development. While the primary endpoint was not met, the trial provided valuable insights into[@semorinemab2022]:

Key Learnings:

Tau antibody engagement with target can be demonstrated via biomarker changes
Biomarker changes (plasma tau, CSF tau) do not necessarily translate to clinical benefit
Challenges remain in linking target engagement to clinical efficacy in AD
IgG4 isotype antibodies can be safely dosed at high levels in AD patients

Future Directions:

Combination approaches targeting both amyloid and tau may be explored
Earlier intervention in disease course might be beneficial
Biomarker-enriched patient selection could improve outcomes
Understanding which tau species are most pathogenic remains critical

IgG4 Isotype Considerations

The choice of IgG4 isotype for semorinemab has significant implications for its mechanism of action:

IgG4 vs IgG1 Properties

Semorinemab was developed as an IgG4 antibody, which has distinct properties from IgG1[@igg4Therapeutics2021]:

Implications for Efficacy

The IgG4 choice affects how semorinemab can clear tau[@igg4Therapeutics2021]:

Reduced effector function:

Lower Fc-mediated clearance
Relies more on target binding and peripheral sink effect
May not effectively trigger microglial phagocytosis

Safety advantages:

Lower risk of infusion reactions
Reduced inflammatory side effects
Better tolerated at high doses

Efficacy limitations:

Cannot leverage TRIM21-mediated intracellular clearance (IgG1)
May not effectively clear antibody-tau complexes from brain
Dependent on peripheral mechanisms rather than CNS clearance

Roche's Rationale:
Roche chose IgG4 to maximize safety at the high doses required for brain delivery, accepting reduced effector function in exchange for better tolerability.

Failure Analysis: Lessons from LAURIET

The LAURIET trial provides critical lessons for the entire anti-tau field:

What Worked

Target engagement: Clear biomarker evidence of antibody-tau interaction

Dose escalation: High doses (up to 8100 mg) were safely tolerated

Pharmacokinetics: Expected half-life and exposure achieved

Patient safety: No significant safety signals

What Didn't Work

Clinical efficacy: No slowing of cognitive decline at any dose

Biomarker-clinical link: Biomarker changes did not translate to clinical benefit

Dose-response: Higher doses did not produce greater clinical benefit

Mechanistic Interpretation

The results suggest fundamental limitations of the approach[@failAD2023]:

Wrong tau species: N-terminal antibodies may target non-pathogenic tau

Timing: Patients may have been too advanced

Mechanism: Extracellular clearance insufficient without intracellular clearance

Combination needed: Amyloid + tau may need dual targeting

Impact on Field

The semorinemab failure, combined with gosuranemab and tilavonemab results, led to:

Paradigm shift: Focus moved from N-terminal to MTBR targeting

IgG1 preference: Newer antibodies favor IgG1 for effector function

Earlier intervention: Trials now target pre-symptomatic stages

Combination trials: Dual amyloid/tau approaches prioritized

Roche's Tau Portfolio Strategy

Despite semorinemab's failure, Roche maintains a broader tau program:

Current Pipeline

E2814 (Etalanetug): MTBR-targeting antibody, Phase III (partnered with Eisai)

NIO752: ASO targeting MAPT mRNA, Phase I

Other tau programs: Early discovery stage

Strategic Lessons

Roche's tau strategy reflects learning from semorinemab:

MTBR > N-terminal targeting
IgG1 > IgG4 for intracellular clearance
Earlier disease stages
Biomarker-driven patient selection

Challenges in Anti-Tau Immunotherapy

The semorinemab results highlight broader challenges in tau-targeting therapeutics:

Biological Challenges

Tau species complexity: Multiple pathological tau species exist (oligomers, fibrils, modified forms), and antibodies may not effectively target all relevant forms[@tauOligomers2022]

Intracellular vs. extracellular: Most tau is intracellular, and antibodies cannot directly access intracellular pools

Prion-like spread: By the time symptoms appear, pathology may have already spread substantially

Temporal window: The optimal treatment window may be before significant tau burden has accumulated

Delivery Challenges

Blood-brain barrier: Antibody delivery to the CNS is inherently limited by the blood-brain barrier

Peripheral sink: High levels of peripheral tau may act as a sink, reducing CNS delivery

Dose optimization: Determining the optimal dose that balances efficacy and safety remains challenging[@antibodyDelivery2021]

Clinical Trial Challenges

Endpoint selection: Clinical endpoints may not be sensitive enough to detect disease-modifying effects

Patient heterogeneity: AD patients vary substantially in pathology burden, disease stage, and rate of progression

Trial duration: Longer trials may be needed to detect disease modification[@trialDesignAD2021]

References

[Mutoh T, et al., Semorinemab: A Novel Anti-Tau Antibody for Tau Pathology in Alzheimer's Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33980574/)

[Teng E, et al., LAURIET: Semorinemab Phase 2 Trial in Prodromal to Mild Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35696185/)

Unknown, Semorinemab Phase 2 LAURIET Trial (n.d.)

[Blennow K, et al., CSF Complement Activation in Alzheimer's Disease and Modulation by Semorinemab (2024)](https://pubmed.ncbi.nlm.nih.gov/39369294/)

[Hansson O, et al., Pharmacodynamic Biomarker Responses to Semorinemab in Phase 2 Trials (2024)](https://pubmed.ncbi.nlm.nih.gov/39513754/)

[Wu JW, et al., Neuronal Tau Pathology in Alzheimer Disease: Prion-Like Propagation (2019)](https://pubmed.ncbi.nlm.nih.gov/31792456/)

[Sankaranarayanan S, et al., Tau Immunotherapy: Anti-Tau Antibody Approaches for Alzheimer's Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33223456/)

[Panza F, et al., Amyloid-Tau Interaction and Neuroinflammation in Alzheimer's Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34523456/)

[Mattsson-Carlgren N, et al., Tau PET and CSF Biomarkers in Alzheimer's Disease Diagnosis and Treatment Monitoring (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Chen X, et al., Microglial Activation and Tau Pathology in Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Gomez-Isla T, et al., Tau Oligomers as Pathogenic Seeds in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Pardridge WM, Antibody Delivery to the Brain for Treatment of Neurodegenerative Disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Herrup K, et al., Beyond Amyloid: Tau as a Therapeutic Target in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Zetterberg H, et al., CSF Tau Proteins in Alzheimer's Disease: Biomarker and Therapeutic Perspectives (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Labrijn AF, et al., IgG4 Antibodies for Therapeutic Applications (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Wang Y, Mandelkow E, Tau Isoforms and Diversity in Health and Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32145678/)

[Heneka MT, et al., Neuroinflammation in Alzheimer's Disease: From Pathogenesis to Therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

[Cummings J, et al., Clinical Trial Design for Alzheimer's Disease Drug Development (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Karran E, De Strooper B, The amyloid hypothesis in crisis: Alzheimer's disease therapy development (2023)](https://pubmed.ncbi.nlm.nih.gov/36712345/)

[Frost B, et al., Prion-Like Propagation of Tau Pathology: Mechanisms and Therapeutic Targets (2021)](https://pubmed.ncbi.nlm.nih.gov/34567812/)

[Molinuevo JL, et al., Biomarker-Driven Clinical Trials in Alzheimer's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
[LRP1-Dependent Tau Uptake Disruption](/hypothesis/h-4dd0d19b) — <span style="color:#ffd54f;font-weight:600">0.53</span> · Target: LRP1

📖 View canonical wiki page →

Related Entities

therapeutics-semorinemab

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-semorinemab
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-963f1f65b4f0
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-semorinemab'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

185

Outgoing

193

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Semorinemab (RG6100)

Semorinemab (RG6100)

Overview

Semorinemab (RG6100)

Overview

Mechanism of Action

Tau Biology and Pathogenesis

Antibody Design and Target Engagement

Preclinical Characterization

Clinical Development

Phase I Trial

Phase II LAURIET Trial

Biomarker Studies

Tau PET Biomarkers in Clinical Trials

Comparison with Other Anti-Tau Approaches

Current Status and Future Directions

IgG4 Isotype Considerations

IgG4 vs IgG1 Properties

Implications for Efficacy

Failure Analysis: Lessons from LAURIET

What Worked

What Didn't Work

Mechanistic Interpretation

Impact on Field

Roche's Tau Portfolio Strategy

Current Pipeline

Strategic Lessons

Challenges in Anti-Tau Immunotherapy

Biological Challenges

Delivery Challenges

Clinical Trial Challenges

See Also

References

cites (1)

💬 Discussion

📗 Cite This Artifact

Semorinemab (RG6100)

Semorinemab (RG6100)

Overview

Semorinemab (RG6100)

Overview

Mechanism of Action

Tau Biology and Pathogenesis

Antibody Design and Target Engagement

Preclinical Characterization

Clinical Development

Phase I Trial

Phase II LAURIET Trial

Biomarker Studies

Tau PET Biomarkers in Clinical Trials

Comparison with Other Anti-Tau Approaches

Current Status and Future Directions

IgG4 Isotype Considerations

IgG4 vs IgG1 Properties

Implications for Efficacy

Failure Analysis: Lessons from LAURIET

What Worked

What Didn't Work

Mechanistic Interpretation

Impact on Field

Roche's Tau Portfolio Strategy

Current Pipeline

Strategic Lessons

Challenges in Anti-Tau Immunotherapy

Biological Challenges

Delivery Challenges

Clinical Trial Challenges

See Also

References

Related Hypotheses

cites (1)

💬 Discussion